Protocol Title:
MCLA-128-CL02: Merus, Ph 2, ER+ & low expression HER2 MBC, MCLA-128/trastuzumab/chemo & MCLA-128/endocrine therapy

Working Title:
MCLA-128-CL02: Merus, Ph 2, ER+ & low expression HER2 MBC, MCLA-128/trastuzumab/chemo & MCLA-128/endocrine therapy

Principal Investigator: MONICA MITA

IRB Approval Number: Pro00052060

Medical Specialty Area: Oncology

Condition Disease: Breast Cancer

IRB Approval Expiration Date: 07/31/2019

Contact Information for patients wishing more information:
Name: Jaime Richardson, RN
Phone: 310-423-2133
Email: cancer.trial.info@cshs.org

If you would like to be contacted regarding this Clinical Trial, leave your contact information.